Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response

Background. Achieving a pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) is a predictive factor for improving disease free and overall survival. In triple negative (TN) and HER2-positive breast cancer (BC), the pCR rate exceeds 60 %. Patients with TN and HER2-positive BC who demonstrate an excellent response to NST are like­ly ideal candidates for downsizing surgery. The condition for reducing the volume of surgical intervention is a reliable determination of pathologic complete response using instrumental imaging and biopsy methods.

Aim. To further assess the accuracy of post-NST image-guided biopsy to predict pCR.

Materials and methods. Sixty one patients with T1-3N0-3 triple negative or HER2-positive BC receiving NST in the Department of Breast Tumors of the NMRC of Oncology named after N.N. Petrov in the period from 2017 to 2019 were enrolled in this single-center retrospective trial. Patients underwent ultrasound-guided core-biopsy of the initial breast tumor region before surgery. Findings were compared with findings on pathologic evaluation of surgical specimens to determine the performance of biopsy in predicting pCR after NST.

Results. After neoadjuvant systemic therapy, clinical partial response (cPR) was diagnosed in 47 (77 %) patients, clinical complete response (cCR) in 14 (23 %) patients. pCR in the core-biopsy tissue and surgical material was achieved in 46 (75.4 %) and 37 (60.7 %), respectively. Performance of image-guided core-biopsy: sensitivity 100 % (95 % confldence interval (CI) 90.51-100), specificity 62.5 % (95 % CI 40.59-81.20), false-negative rate (FNR) 0 %, positive-pre­dictive value (PPV) 75.00 % (95 % CI 59.46-85.99), negative predictive value (NPV) 100.00 %.

Conclusion. This retrospective trial showed that ultrasound-guided core biopsies are accurate enough to identify breast pCR in patients with triple-negative or HER2-positive BC with good response after NST (FNR 0 %). Based on these results, a prospective clinical trial has commenced in which breast surgery is omitted in patients with a breast pCR after NST according to image-guided biopsy.

1. Von Minckwitz G., Untch M., Blohmer J.U. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30(15):1796-804. DOI: 10.1200/JCO.2011.38.8595

2. Semiglazov V.F. Neoadjuvant systemic therapy for breast cancer. Voprosy Onkologii 2015;61(2):162-8.

3. Sikov W.M., Berry D.A., Perou C.M. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33(1):13-21. DOI: 10.1200/JCO.2014.57.0572

4. Schneeweiss A., Chia S., Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24(9):2278-84. DOI: 10.1093/annonc/mdt182

5. Mieog J.S., van der Hage J.A., van de Velde C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;2007(2):CD005002. DOI: 10.1002/14651858.CD005002.pub2

6. Shin H.C., Han W., Moon H.G. et al. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol 2013;20(8):2582-9. DOI: 10.1245/s10434-013-2909-6

7. Morrow M., Khan A.J. Locoregional management after neoadjuvant chemotherapy. J Clin Oncol 2020;38(20):2281-9. DOI: 10.1200/JCO.19.02576

8. Shin H.J., Kim H.H., Ahn J.H. et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 2011;84(1003):612-20. DOI: 10.1259/bjr/74430952

9. Krivorotko P.V., Novikov S.N., Kanaev S.V. Interpretetion of 99mTc-scintigraphy results in breast cancer patients. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2013(6):24-31. (In Russ.)

10. Tasoulis M.K., Heil J., Kuerer H.M. De-escalating surgery among patients with ER2+ and triple negative breast cancer. Curr Breast Cancer Rep 2022:1-7. DOI: 10.1007/s12609-022-00453-3

11. Flanagan M.R., Zabor E.C., Romanoff A. et al. A comparison of patient-reported outcomes after breast-conserving surgery and mastectomy with implant breast reconstruction. Ann Surg Oncol 2019;26:3133-40.

12. Gartner R., Jensen M.B., Nielsen J. et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009;302:1985-92.

13. Giuliano A.E., Ballman K.V., McCall L. et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017;318:918-26.

14. Hennigs A., Kopke M., FeiBt M. et al. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice? Breast Cancer Res Treat 2019;173:429-38.

15. Tasoulis M.K., Lee H.B., Yang W. et al. Accuracy of post¬neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg 2020;155(12):e204103. DOI: 10.1001/jamasurg.2020.4103

16. Ring A., Webb A., Ashley S. et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol 2003;21(24):4540-5. DOI: 10.1200/JCO.2003.05.208

17. Ozkurt E., Sakai T., Wong S.M. et al. Survival outcomes for patients with clinical complete response after neoadjuvant chemotherapy: is omitting surgery an option? Ann Surg Oncol 2019;26(10):3260-8. DOI: 10.1245/s10434-019-07534-1